Zentalis Pharmaceuticals Llc Stock Price Patterns
| ZNTL Stock | USD 2.39 0.05 2.14% |
Momentum 50
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.48) | EPS Estimate Current Year (1.94) | EPS Estimate Next Year (1.81) | Wall Street Target Price 5.3125 | EPS Estimate Current Quarter (0.48) |
Using Zentalis Pharmaceuticals hype-based prediction, you can estimate the value of Zentalis Pharmaceuticals Llc from the perspective of Zentalis Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Zentalis Pharmaceuticals using Zentalis Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Zentalis using crowd psychology based on the activity and movement of Zentalis Pharmaceuticals' stock price.
Zentalis Pharmaceuticals Implied Volatility | 2.0 |
Zentalis Pharmaceuticals' implied volatility exposes the market's sentiment of Zentalis Pharmaceuticals Llc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zentalis Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zentalis Pharmaceuticals stock will not fluctuate a lot when Zentalis Pharmaceuticals' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Zentalis Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Zentalis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Zentalis Pharmaceuticals after-hype prediction price | USD 1.88 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Zentalis contract
Based on the Rule 16, the options market is currently suggesting that Zentalis Pharmaceuticals Llc will have an average daily up or down price movement of about 0.13% per day over the life of the 2026-04-17 option contract. With Zentalis Pharmaceuticals trading at USD 2.39, that is roughly USD 0.002988 . If you think that the market is fully incorporating Zentalis Pharmaceuticals' daily price movement you should consider acquiring Zentalis Pharmaceuticals Llc options at the current volatility level of 2.0%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Zentalis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Zentalis Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Zentalis Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zentalis Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Zentalis Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Zentalis Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Zentalis Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zentalis Pharmaceuticals' historical news coverage. Zentalis Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.09 and 10.68, respectively. We have considered Zentalis Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Zentalis Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Zentalis Pharmaceuticals is based on 3 months time horizon.
Zentalis Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Zentalis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zentalis Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zentalis Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.30 | 8.80 | 0.51 | 0.16 | 7 Events / Month | 7 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.39 | 1.88 | 21.34 |
|
Zentalis Pharmaceuticals Hype Timeline
Zentalis Pharmaceuticals is at this time traded for 2.39. The entity has historical hype elasticity of -0.51, and average elasticity to hype of competition of -0.16. Zentalis is anticipated to decline in value after the next headline, with the price expected to drop to 1.88. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -21.34%, whereas the daily expected return is at this time at 1.3%. The volatility of related hype on Zentalis Pharmaceuticals is about 7272.73%, with the expected price after the next announcement by competition of 2.23. About 22.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.61. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 7 days. Check out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Zentalis Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Zentalis Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Zentalis Pharmaceuticals' future price movements. Getting to know how Zentalis Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zentalis Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PLRX | Pliant Therapeutics | (0.02) | 9 per month | 0.00 | (0.17) | 4.59 | (6.82) | 22.72 | |
| ARTV | Artiva Biotherapeutics Common | (0.35) | 5 per month | 7.28 | 0.05 | 8.00 | (11.11) | 118.69 | |
| TIL | Instil Bio | (0.18) | 6 per month | 0.00 | (0.1) | 6.59 | (9.97) | 55.58 | |
| IMMX | Immix Biopharma | (0.44) | 7 per month | 3.74 | 0.22 | 14.88 | (6.08) | 28.79 | |
| STTK | Shattuck Labs | 0.30 | 9 per month | 3.04 | 0.23 | 6.42 | (4.91) | 27.88 | |
| STRO | Sutro Biopharma | (0.99) | 7 per month | 4.62 | 0.19 | 11.87 | (7.78) | 29.10 | |
| ALXO | Alx Oncology Holdings | 0.15 | 7 per month | 5.23 | 0.15 | 13.04 | (9.02) | 23.85 | |
| MGNX | MacroGenics | 0.11 | 6 per month | 2.96 | 0.07 | 6.83 | (5.00) | 24.44 | |
| WHWK | Whitehawk Therapeutics | 0.22 | 6 per month | 3.44 | 0.10 | 6.98 | (5.32) | 21.49 | |
| DTIL | Precision BioSciences | (0.01) | 7 per month | 0.00 | (0.17) | 5.99 | (7.57) | 15.28 |
Zentalis Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Zentalis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zentalis using various technical indicators. When you analyze Zentalis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Zentalis Pharmaceuticals Predictive Indicators
The successful prediction of Zentalis Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Zentalis Pharmaceuticals Llc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Zentalis Pharmaceuticals based on analysis of Zentalis Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Zentalis Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Zentalis Pharmaceuticals's related companies. | 2025 | 2026 (projected) | Days Sales Outstanding | 31.13 | 29.57 | PTB Ratio | 0.73 | 0.7 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. Anticipated expansion of Zentalis directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zentalis Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zentalis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.